Our Science
Our Focus:
Myeloproliferative Neoplasms
We are addressing the unmet need in patients with forms of chronic blood cancer known as myeloproliferative neoplasms (MPNs).
MPNs begin with mutations occurring in stem cells in the bone marrow. While currently available treatments provide symptomatic benefit, they do not eliminate the disease driving stem cells, meaning patients have poor prognosis.
Identifying new drug targets within these mutant stem cells is critical to developing new and potentially curative therapies.
Our Platform: TARGET-seq
The Alethiomics TARGET-seq platform uses multi-omic information from single cells to provide a holistic understanding of disease, and more intelligent target identification. It is the only platform capable of uncoupling single cell tumour heterogeneity at high resolution and with ultra-high sensitivity.
TARGET-seq provides us with a powerful way to identify new targets in the cancer stem cells that drive and propagate disease.
Our Goal: Novel Therapies
TARGET-seq has enabled us to identify novel strategies to target MPN stem cells.
Based on these discoveries, we are now developing therapeutics that we will advance through discovery to clinical development.
TARGET-seq has considerable potential in other indications that are driven by mutations. We will be utilising the platform to discover new targets in other cancers and beyond.
Images copyright MRC Weatherall Institute of Molecular Medicine, University of Oxford